INDIANAPOLIS — An Indiana University cancer researcher has been awarded a $200,000 grant from the Conquer Cancer Foundation of the American Society of Clinical Oncology.
Costantine Albany, M.D., assistant professor of clinical medicine at the IU School of Medicine and a researcher at the Indiana University Melvin and Bren Simon Cancer Center, is among nine recipients of the foundation’s Career Development Award. The three-year award provides funding to clinical investigators who have recently received a faculty appointment at an academic center to perform patient-oriented cancer research.
Dr. Albany is studying whether the drug SGI-110 makes resistant testis cancer respond again to cisplatin chemotherapy. Metastatic testis cancer is highly curable with the use of a combination of chemotherapy drugs that contains a drug called cisplatin. However, about 10 percent to 20 percent of metastatic testis cancers are resistant to cisplatin chemotherapy. Dr. Albany’s work has the potential to change resistant incurable testis cancer to a curable disease.
Dr. Albany’s primary expertise is in testicular cancer and prostate cancer. His research focuses on identifying new therapeutic targets.
He earned his medical degree from Techreen University, Lattakia, Syria. He completed residencies at the American University, Beirut, Lebanon, and St. Luke’s Roosevelt Hospital Center, New York. He completed his fellowship at the IU School of Medicine.